FinCanna Capital Corp (CSE:CALI) (“FinCanna”) a royalty company for the U.S. licensed medical cannabis industry is pleased to announce the appointment of Mr. Robert Kamm to its Board of Directors.

Mr. Kamm has over 25 years of experience operating and advising businesses from large Fortune 500 corporations to venture capital backed companies and has served on Boards of Directors of both public and private companies during this time period. He also formerly held the position of Vice President of Union Bank, Los Angeles. Mr. Kamm currently represents FinCanna on the Board of Directors of Cultivation Technologies Inc., a FinCanna investee company.

Mr. Kamm is currently a principle and the Entrepreneur in Residence at Sandy Hill Venture Capital. Founded in 2007, Sandy Hill is a San Francisco Bay area firm that invests in and advises emerging business in the Clean Tech, Fintech, Healthcare, Internet Security, and Software industries. Mr. Kamm is an active participant in the Bay Area investment community and is an original and active member of the Keiretsu Forum. Founded in 2007 the Keiretsu Forum is a global investment community of over 2,500 accredited private equity angel investors, venture capitalists and corporate/institutional investors. It is one of the largest angel investment organizations globally with 52 chapters on 3 continents, whose members to date have invested over $800 million dollars in over 800 companies.

Mr. Kamm is also an active member of Pitchforce, a San Francisco based forum that assists young entrepreneurs seeking venture capital. Mr. Kamm holds a Masters of Business Administration degree in finance and strategy from UCLA.

“We are very pleased to welcome Mr. Kamm to our Board of Directors,” said Andriyko Herchak, President and CEO of FinCanna Capital. “Bob has a wide range of business expertise and skills all of which will serve us well as we begin to accelerate our growth trajectory over this next time period. He has an exceptional history of identifying and building high growth companies and we look forward to him applying his talents to the future success of FinCanna. I would also like to thank Mr. Jeff Tindale for his invaluable service on our Board of Directors since FinCanna’s inception and welcome his continued involvement with FinCanna on our Board of Advisors.”

“I am delighted to be joining the Board of FinCanna,” said Mr. Kamm. “I’ve been actively involved in the cannabis space since 2016 and see an enormous opportunity in the US and California in particular. I believe the FinCanna royalty business model is ideally suited to support the industry as it breaks out into its next level of growth. I’ve spent most of my career identifying, analysing and building high growth companies and I look forward to applying my skill set with FinCanna. The company has assembled a solid portfolio of royalty investments and I welcome the opportunity to play an integral role with the FinCanna team as it pursues its continued development and expansion.”

Mr. Jeff Tindale has resigned from the FinCanna Board of Directors making way for Mr. Kamm’s appointment. Mr. Tindale will continue to act on FinCanna’s Board of Advisors.

On August 29, 2018 FinCanna issued a total of 450,000 incentive stock options to a director and an advisor with an exercise price of $0.30 per share and a term of five years.

About FinCanna Capital Corp.

FinCanna provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on revenues. FinCanna, led by a team of finance and industry experts, is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in U.S. legal states, with a focus on California. For additional information visit and FinCanna’s profile at

FinCanna Capital Corp.
Andriyko Herchak, CEO & Director

Investor Relations:

Arlen Hansen
Kin Communications

Cautionary Note Regarding Forward-Looking Statements
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about how the developing U.S. legal regime will impact the cannabis industry. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the CSE listing statement and other reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

Click here to connect with FinCanna Capital Corp (CSE:CALI) for an Investor Presentation.


Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less